P

Pratia | Centrum Medyczne Pratia Gdynia

Research site
(Unclaimed)
Location
Chrzanowskiego 3/5, Gdynia, Pomerania, Poland

Site insights

Top conditions

Top treatments

Upadacitinib
ABT-494
Atogepant
Semaglutide
TAK-279
Filgotinib
Methotrexate
MTX
Sugar
ABX464

Parent organization

This site is a part of Pratia

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 33 total trials

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic o...

Active, not recruiting
Chronic Migraine
Episodic Migraine
Drug: Atogepant 60 mg

This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the inv...

Active, not recruiting
Obesity
Drug: Placebo
Drug: Semaglutide

This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be inv...

Enrolling
Diabetes, Type 2
Drug: Insulin glargine
Drug: Insulin icodec

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate t...

Enrolling
Crohn's Disease
Drug: TAK-279
Drug: Placebo

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: TAK-279

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis wh...

Active, not recruiting
Psoriatic Arthritis
Drug: Deucravacitinib
Other: Placebo

This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as mainten...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy,...

Active, not recruiting
Osteoporosis, Postmenopausal
Biological: Denosumab

The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the...

Active, not recruiting
Rheumatoid Arthritis
Drug: Filgotinib
Drug: Placebo to match filgotinib
Locations recently updated

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular...

Enrolling
Cardiovascular Disease
Drug: Semaglutide
Drug: Cagrilintide

Trial sponsors

AbbVie logo
Novo Nordisk logo
Pfizer logo
A
Allergan logo
Takeda logo
Amgen logo
Bristol-Myers Squibb (BMS) logo
G
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems